Abstract
The interaction of non-phosphorylated L-type pyruvate kinase (L-PK) with fructose 1,6-bisphosphate (FBP), which is an allosteric activator of the phosphorylated enzyme, and peptides that mimic the phosphorylatable N-terminal regulatory domain of the enzyme, was studied. It was found that the catalytic activity of the enzyme was not enhanced in the presence of FBP, and this ligand acted as a relatively weak reversible inhibitor of the enzyme activity in the micromolar concentration range. The phosphorylation site analogue peptides RRASVA and RRAAVA had no effect on the activity of the enzyme, while the phosphorylated peptide RRAS(Pi)VA reversibly inhibited the enzyme and this process was characterised by the Ki value 47 μM. As the phosphorylated form of L-PK is a subject of significant allosteric regulation by FBP, it was concluded that phosphorylation should function as a molecular switch of the allosteric properties of this enzyme.
Keywords: Allosteric effector, fructose 1, 6-bisphosphate, L-type pyruvate kinase, N-terminal domain, peptide, phosphoenolpyruvate.
Protein & Peptide Letters
Title:Interaction of Non-Phosphorylated Liver Pyruvate Kinase with Fructose 1,6-Bisphosphate and Peptides that Mimic the Phosphorylatable N-terminus of the Enzyme
Volume: 20 Issue: 11
Author(s): Ilona Faustova and Jaak Järv
Affiliation:
Keywords: Allosteric effector, fructose 1, 6-bisphosphate, L-type pyruvate kinase, N-terminal domain, peptide, phosphoenolpyruvate.
Abstract: The interaction of non-phosphorylated L-type pyruvate kinase (L-PK) with fructose 1,6-bisphosphate (FBP), which is an allosteric activator of the phosphorylated enzyme, and peptides that mimic the phosphorylatable N-terminal regulatory domain of the enzyme, was studied. It was found that the catalytic activity of the enzyme was not enhanced in the presence of FBP, and this ligand acted as a relatively weak reversible inhibitor of the enzyme activity in the micromolar concentration range. The phosphorylation site analogue peptides RRASVA and RRAAVA had no effect on the activity of the enzyme, while the phosphorylated peptide RRAS(Pi)VA reversibly inhibited the enzyme and this process was characterised by the Ki value 47 μM. As the phosphorylated form of L-PK is a subject of significant allosteric regulation by FBP, it was concluded that phosphorylation should function as a molecular switch of the allosteric properties of this enzyme.
Export Options
About this article
Cite this article as:
Faustova Ilona and Järv Jaak, Interaction of Non-Phosphorylated Liver Pyruvate Kinase with Fructose 1,6-Bisphosphate and Peptides that Mimic the Phosphorylatable N-terminus of the Enzyme, Protein & Peptide Letters 2013; 20 (11) . https://dx.doi.org/10.2174/09298665113209990008
DOI https://dx.doi.org/10.2174/09298665113209990008 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Epigenetics and Sjogren’s Syndrome
Current Pharmaceutical Biotechnology Genetic and Molecular Basis of QTL of Diabetes in Mouse: Genes and Polymorphisms
Current Genomics Point of NO Return for Nitrergic Nerves in Diabetes: A New Insight into Diabetic Complications
Current Pharmaceutical Design Subject Index To Volume 7
Current Pharmaceutical Design Role of Endogenous Androgen Against Insulin Resistance and Athero-sclerosis in Men with Type 2 Diabetes
Current Diabetes Reviews Androgen Therapy in Male Patients Suffering from Type 2 Diabetes: A Review of Benefits and Risks
Current Diabetes Reviews Consequences of Aberrant Insulin Regulation in the Brain: Can Treating Diabetes be Effective for Alzheimers Disease
Current Neuropharmacology Applications of Random Walk Model on Biological Networks
Current Bioinformatics Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease
Current Vascular Pharmacology The Role of Diet in Patients with Metabolic Syndrome
Current Medicinal Chemistry Ligand-receptor Engineering and its Application Towards the Complementation of Genetic Disease and Target Identification
Current Topics in Medicinal Chemistry Rationally Designed Multi-Targeted Agents Against Neurodegenerative Diseases
Current Medicinal Chemistry Calcium-engaged Mechanisms of Nongenomic Action of Neurosteroids
Current Neuropharmacology Critical Role of Dipeptidyl Peptidase IV: A Therapeutic Target for Diabetes and Cancer
Mini-Reviews in Medicinal Chemistry Stage A: Can Heart Failure Be Prevented?
Current Cardiology Reviews The Potent Inhibitory Effect of β-D-Mannuronic Acid (M2000) as a Novel NSAID with Immunosuppressive Property on Anti-Cyclic Citrullinated Peptide Antibodies, Rheumatoid Factor and Anti-dsDNA Antibodies in Patients with Rheumatoid Arthritis
Current Drug Discovery Technologies Do Statins Beneficially or Adversely Affect Glucose Homeostasis?
Current Vascular Pharmacology Data-driven Approach to Detect and Predict Adverse Drug Reactions
Current Pharmaceutical Design Natural Steroids and Androgen Antagonists used as Neuroprotection in Common Neurological Disorders
CNS & Neurological Disorders - Drug Targets Chemical Changes in Dairy Products Resulting from Cholesterol Removal Using Beta Cyclodextrins
Current Nutrition & Food Science